Organization | Air Force Military Medical University, China

Air Force Military Medical University, China Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial

2012

NCT01694823

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Air Force Military Medical University, China | Mei Shi | Shengqing Li

Active Ingredients

Drugs in Phase 3 Trials (3)

cisplatin (platinol) (1 trial)

docetaxel (taxotere) (1 trial)

nadroparin (1 trial)

Drugs in Phase 2 Trials (1)

autologous culture chondrocytes (Carticel) (1 trial)

Drugs in Phase 1 Trials (1)

low density lipoprotein receptor mrna exosomes (1 trial)

Drugs in Other Trials (8)

azacitidine (vidaza) (1 trial)

bean powder (1 trial)

magnesium sulfate (Tis-U-Sol) (1 trial)

omacetaxine (synribo) (1 trial)

phosphatidylserine (1 trial)

polyethylene glycol (1 trial)

propofol (diprivan) (1 trial)

remimazolam (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Joint Diseases (Phase 2)

Lung Neoplasms (Phase 3)

Osteochondritis (Phase 2)

Osteochondritis Dissecans (Phase 2)

Thromboembolism (Phase 3)

Uterine Cervical Neoplasms (Phase 3)

Venous Thromboembolism (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial APIs: 13